Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Allakos (NASDAQ:ALLK) has dropped ~75% in premarket trading Monday after posting disappointing phase 1 results on AK006 for chronic spontaneous urticaria and deciding to end development. Due to ...

Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients ...

A pandemic is not inevitable, scientists say. But the outbreak has passed worrisome milestones in recent weeks, including ...

Eight of the hostages due for release in the first phase of a truce deal between Israel and Hamas are dead, Israeli ...

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...

UEFA.com delves into the UEFA Champions League archive to unearth some memorable encounters from the last matchday of the ...

Advisor to the Prime Minister and Official Spokesperson for the Ministry of Foreign Affairs (MoFA) HE Dr. Majed bin Mohammed ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

A significant milestone was reached on Friday afternoon with the opening of the second completed section of the Monon South ...